



The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

614.ACUTE LYMPHOBLASTIC LEUKEMIAS: THERAPIES, EXCLUDING TRANSPLANTATION AND CELLULAR IMMUNOTHERAPIES**Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL)**

Jayastu Senapati, MD¹, Hagop M. Kantarjian, MD¹, Elias Jabbour, MD¹, Rodrick Babakhanlou, MD², Tapan M. Kadia, MD¹, Gautam Borthakur, MD¹, Marina Y. Konopleva, MD PhD^{3,1}, William G. Wierda, MD PhD⁴, Jan A. Burger, MD PhD⁵, Ghayas C. Issa, MD⁴, Abhishek Maiti, MD⁵, Hayley S. Balkin², Mary Kelly², Rebecca Garris¹, Alessandra Ferrajoli, MD¹, Guillermo Garcia-Manero, MD⁴, Yesid Alvarado Valero, MD¹, Partow Kebriaei, MD⁶, Nicholas J. Short, MD¹, Nitin Jain, MD¹, Farhad Ravandi, MD MBBS¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

³Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY

⁴The University of Texas MD Anderson Cancer Center, Houston, TX

⁵Department of Leukemia, MD Anderson Cancer Center, Houston, TX

⁶Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Background:

The incorporation of novel agents such as NEL and PEG to frontline therapy has been associated with improved outcomes in pediatric patients (pts) with T-ALL/LBL, but has not been extensively studied in the adult pts. BCL-2 upregulation has been demonstrated in T-lymphoblasts, especially of the early T-cell precursor (ETP) ALL and addition of VEN (BCL-2 inhibitor) may be beneficial.

Methods:

Pts with previously untreated or minimally pre-treated T-ALL/LBL were eligible if they had an ECOG PS ≤ 3 , creatinine ≤ 2 mg/dL, total bilirubin ≤ 2 mg/dL and ALT/AST $\leq 4 \times$ ULN. Pts received 8 cycles (C) of HCVAD (C 1,3, 5, 7) alternating with high dose Ara-C and methotrexate (MTX) (C 2, 4, 6, 8) at approximately 3-week intervals. Two cycles of NEL (650 mg/m² daily x 5) were initially administered after C8 (cohort 1). Later, after a protocol amendment, they were administered after C4 and C5 (cohort 2). Subsequently, the protocol was amended to add PEG (1500 IU/m² capped at 3750 IU; for pts age 60 or older, dose was 1000 IU/m², capped at 2000 IU) on day 5 of the NEL cycles (cohort 3) and more recently, VEN 400 mg daily was added on the first 7 days of each of 8 cycles of therapy (cohort 4); this was later modified to be given for 7 days during the induction cycle to all pts and reduced to 3 days per post-induction cycle only in pts with ETP-ALL or those with persistent measurable residual disease (MRD) and all other pts did not receive VEN after C1 (cohort 5). Pts with ETP-ALL were referred for allogeneic stem cell transplant (allo-SCT) in first complete remission (CR). After the completion of the intensive phase; pts in all cohorts received 30 cycles of maintenance therapy with monthly POMP (prednisone, vincristine, MTX, prednisone) and early intensification with NEL/PEG on C6 and 7 and late intensification with MTX/PEG in C18 and HCVAD on C19. All pts received 8 intrathecal chemotherapy with MTX alternating with Ara-C and mediastinal radiation was considered in pts with bulky mediastinal disease.

Results:

Between 7/2007 and 12/2022, 133 pts were enrolled in the 5 study cohorts sequentially (cohort 1= 30, 2= 49, 3=17, 4=16, 5=21) (**Table 1**). Eighty pts (60%) had T-ALL, 52 T-LBL (39%) and 1 pt had ETP/myeloid bi-phenotypic leukemia. The median age for the entire cohort was 35 years (yrs) (range 18-78), 102 pts were male (77%), 83 pts (62%) were white and 18 pts (14%) had PS ≥ 2 . Overall, 24 pts (18%) had an ETP phenotype and another 19 pts (14%) had a near-ETP phenotype. Six pts (5%) had central nervous system disease at diagnosis, 72 pts (54%) had mediastinal disease, 49 of 80 (61%) T-ALL pts had extramedullary disease and 20 pts (15%) were in complete remission (CR) at trial enrollment after minimal pre-enrollment therapy. Overall response (CR+CRp+CRi+PR) on trial was attained in 109/113 (95%) pts [CR= 101 (89%), CRi/CRp= 3 (3%), PR=5 (4%)]. CR/CRi/CRp was

attained in 36/41 (88%) pts with ETP/near-ETP ALL and 60/64 (94%) of confirmed near-ETP ALL pts ($p=0.31$). At a median follow-up of 62 months (mos), the median overall survival (OS) was not reached (NR), 3-yr OS was 71% and 5-yr OS was 64%. The 3-yr OS for pts treated with HCVAD+NEL (cohort 1+2), HCVAD+NEL+PEG (Cohort 3) and HCVAD+NEL+PEG+VEN (Cohort 4+5) were 66%, 88% and 76% respectively (**Figure 1**). Median OS was not reached for both VEN cohorts, while 3-yr OS was 72% in cohort 4 compared to 88% in cohort 5 ($p=0.51$), with significantly shorter follow-up for the latter (33 mos vs. 15 mos). Amongst the 124 pts who had CR/CRp/CRi, the median RFS was NR and 5-yr RFS was 68%. 24 (18%) pts underwent SCT in first remission, including 20 (83%) with ETP or near-ETP ALL. The median OS was shorter in the 44 ETP/near-ETP pts compared to the 77 pts with non-ETP phenotype (71 mos vs. NR, $p=0.08$). 30 and 60-day mortality was 0% and 1%. 10 pts (7.5%) died in remission (3, 5 and 2 pts in cohorts 1, 2 and 4 respectively) including 1 after SCT, 4 after developing therapy-related acute myeloid leukemia and 5 from infectious complications.

Conclusion: The ongoing phase 2 trial of NEL, ASP, VEN added to the HCVAD regimen shows promising long-term survival in adult pts with T-ALL/LBL with 3-yr OS of 76%-88% in pts treated with HCVAD+NEL+PEG +/- VEN. Larger prospective trials and longer follow-up are needed to demonstrate further benefit.

Disclosures Senapati: Kite Pharma: Other: Advisory Board. **Kantarjian:** Novartis: Honoraria; KAHr Medical: Honoraria; Jazz Pharmaceuticals (Inst): Honoraria, Research Funding; Ipsen: Honoraria; Immunogen (Inst): Honoraria, Research Funding; Daiichi-Sankyo (Inst): Honoraria, Research Funding; AstraZeneca/MedImmune: Honoraria; Astellas Pharma: Honoraria; Ascentage Pharma Group: Honoraria; Amgen: Honoraria; Abbvie: Consultancy, Honoraria; Pfizer: Honoraria; Taiho Pharmaceutical: Honoraria; Precision Biosciences: Honoraria; Shenzhen Target Rx: Honoraria; Abbvie (Inst): Research Funding; Ascentage Pharma (Inst): Research Funding; Amgen (Inst): Research Funding; Bristol-Myers Squibb (Inst): Research Funding; Novartis (Inst): Research Funding. **Jabbour:** Ascentage Pharma Group: Consultancy, Honoraria, Research Funding; Adaptive Biotech: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Hikma Pharmaceuticals: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding. **Kadia:** Celgene: Research Funding; Iterion: Research Funding; Sanofi-Aventis: Consultancy; Daiichi Sankyo, Genentech, Inc., Genzyme, Jazz Pharmaceuticals, Liberum, Novartis, Pfizer, PinotBio, Inc, Pulmotect, Inc, Sanofi-Aventis, Servier: Consultancy; Genzyme: Honoraria; Hikma Pharmaceuticals: Speakers Bureau; Amgen, Inc.: Research Funding; Astellas Pharma Global Development: Research Funding; Novartis: Consultancy; Cellenkos Inc.: Research Funding; Cure: Speakers Bureau; Jazz Pharmaceuticals, Pfizer, Pulmotect, Inc, Regeneron Pharmaceuticals, SELLAS Life Sciences Group: Research Funding; Janssen Research and Development: Research Funding; AbbVie, Amgen, Inc, Ascentage Pharma Group, Astellas Pharma Global Development, Astex, AstraZeneca, BMS, Celgene, Cellenkos Inc, Cyclacel, Delta-Fly Pharma, Inc, Genentech, Inc., Genfleet, Glycomimetics, Iterion, Janssen Research and Development: Research Funding; Liberum: Consultancy; Biologix, Cure, Hikma Pharmaceuticals: Speakers Bureau; Glycomimetics: Research Funding; Pulmotect, Inc.: Consultancy, Research Funding; Agios: Consultancy; Genentech: Consultancy, Research Funding; Delta-Fly Pharma, Inc.: Research Funding; GenFleet Therapeutics: Research Funding; Cyclacel: Research Funding; Pfizer: Consultancy, Research Funding; AstraZeneca: Research Funding; Ascentage Pharma Group: Research Funding; Regeneron Pharmaceuticals: Research Funding; SELLAS Life Sciences Group: Research Funding; Servier: Consultancy; PinotBio: Consultancy; BMS: Consultancy, Research Funding; Astex: Honoraria. **Borthakur:** Astex Pharmaceuticals, Ryvu, PTC Therapeutics: Research Funding; Pacylex, Novartis, Cytomx, Bio Ascend.: Membership on an entity's Board of Directors or advisory committees; Catamaran Bio, Abbvie, PPD Development, Protagonist Therapeutics, Janssen: Consultancy. **Konopleva:** Reata Pharmaceuticals.: Current holder of stock options in a privately-held company, Patents & Royalties; Abbvie, Allogene Therapeutics, Collectis, Forty Seven, Gilead Sciences, Genentech, Sanofi, MEI Pharma, Rafael Pharmaceuticals, Daiichi Sankyo Pharmaceutical, AstraZeneca Co., Menarini, Precision BioSciences.: Research Funding; AbbVie, Forty Seven, Precision Biosciences, Gilead Sciences, Genentech, Janssen, Sanofi, MEI Pharma, Daiichi Sankyo Pharmaceutical, AstraZeneca Co., Menarini.: Consultancy. **Wierda:** NIH P30 CA016672/MDACC Cancer Center Support Grant: Research Funding; GSK/Novartis: Research Funding; Nurix Therapeutics: Research Funding; AstraZeneca/Acerta Pharma: Consultancy, Research Funding; Numab Therapeutics: Research Funding; Oncternal Therapeutics, Inc.: Research Funding; Juno Therapeutics: Research Funding; Janssens Biotech: Research Funding; Cyclacel: Consultancy, Research Funding; GlaxoSmithKline: Research Funding; Loxo Oncology, Inc./Lilly: Research Funding; Janssens Biotech Inc: Research Funding; Gilead Sciences: Research Funding; Pharmacyclics LLC: Research Funding; AbbVie: Consultancy, Research Funding; Genentech: Research Funding; Accutar Biotechnology: Research Funding; National Comprehensive Cancer Network: Other: Nonrelevant Financial Relationship/Chair, CLL). Supported by the NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources; Miragen: Research Funding; Sunesis: Research Funding; KITE Pharma: Research Funding; Bristol Myers Squibb (Juno & Celgene): Consultancy, Research Funding. **Burger:** Abbvie, Beigene: Research Funding; Janssen: Other: Speaker fees and Travel Support; AstraZeneca, Pharmacyclics: Other: Advisory Board, Research Funding. **Issa:** Merck: Research Funding; Novartis: Consultancy, Research Funding; Kura Oncology: Consultancy, Research Funding; Syndax: Research Funding; NuProbe: Consultancy; Celgene: Research Funding. **Maiti:** Lin BioScience: Research Funding; Celgene: Research Funding. **Ferrajoli:** Beigene: Research Funding; GenMab: Research Funding; Genetech: Honoraria; AstraZeneca: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Janssen: Honoraria. **Garcia-Manero:** Genentech: Research Funding; Bristol Myers Squibb: Other: Medical writing support, Research Funding; AbbVie: Research Funding. **Alvarado Valero:** Jazz: Research Funding; FibroGen: Research Funding; MEI Pharma: Research Funding; Daiichi-Sankyo: Research Funding; Astex: Research Funding; Sun Pharma:

Consultancy, Research Funding; *CytomX Therapeutics*: Consultancy; *BerGenBio*: Research Funding. **Kebriaei**: *Pfizer*: Consultancy, Honoraria; *Jazz*: Consultancy, Honoraria. **Short**: *AstraZeneca*: Consultancy; *Takeda*: Consultancy, Research Funding; *Astellas*: Research Funding; *Amgen*: Honoraria; *Stemline therapeutics*: Research Funding; *Novartis*: Consultancy; *Pfizer*: Consultancy. **Jain**: *Cellectis*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *TransThera Sciences*: Research Funding; *Mingsight*: Research Funding; *BMS*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Janssen*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; *Adaptive Biotechnologies*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Dialectic Therapeutics*: Research Funding; *AbbVie*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Novalgen*: Research Funding; *Fate Therapeutics*: Research Funding; *AstraZeneca*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *CareDX*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; *MEI Pharma*: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; *Takeda*: Research Funding; *Ipsen*: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; *Medisix*: Research Funding; *Pfizer*: Research Funding; *Pharmacyclics*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Loxo Oncology*: Research Funding; *TG Therapeutics*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; *Genentech*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Beigene*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; *Newave*: Research Funding; *Precision Biosciences*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Kite/Gilead*: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Incyte*: Research Funding; *Servier*: Research Funding; *Aprea Therapeutics*: Research Funding; *ADC Therapeutics*: Research Funding. **Ravandi**: *Prelude*: Research Funding; *Biomea fusion*: Honoraria, Research Funding; *Xencor*: Research Funding; *Celgene/BMS*: Consultancy, Honoraria, Research Funding; *Amgen*: Honoraria, Research Funding; *Syros*: Consultancy, Honoraria, Research Funding; *Abbvie*: Consultancy, Honoraria, Research Funding; *Astellas*: Consultancy, Honoraria, Research Funding; *Astex/taiho*: Membership on an entity's Board of Directors or advisory committees, Research Funding.

Table 1: Baseline characteristics and response

	N(%),[range]					
N	133	30	49	17	16	21
Median age	35 [18-78]	38 [19-76]	33 [18-78]	31 [18-65]	38 [18-52]	33 [20-62]
Male	102 (77)	22 (73)	39 (80)	14 (82)	12 (75)	15 (71)
ECOG PS ≥2	18 (14)	3 (10)	7 (14)	3 (18)	3 (19)	2 (10)
T-ALL, T-LL	80 (60), 52 (39)	19 (63), 11 (37)	28 (57), 20 (41)	9 (53), 8 (47)	11 (69), 5 (31)	13 (62), 8 (38)
CNS +ve at Diagnosis	6 (5)	2 (7)	2 (4)	1 (6)	1 (6)	0
Mediastinal disease	72 (54)	16 (53)	24 (49)	8 (47)	8 (50)	16 (76)
WBC (10 ⁹ /L)	7.8 [0.5-344.3]	7.6 [0.6-241.4]	7.7 [1.2-309.2]	7.4 [0.5-86.3]	9.3 [1.4-344.3]	11.3 [1.7-150.7]
BM Blast (%)	20 [0-97]	19.5 [0-95]	9 [0-96]	30 [1-94]	39 [0-90]	25 [1-97]
Immunophenotype						
Thymic	59 (44)	10 (33)	20 (41)	9 (53)	10 (63)	10 (48)
ETP	24 (18)	6 (20)	10 (20)	5 (29)	2 (13)	1 (5)
Near ETP	20 (15)	7 (23)	7 (14)	1 (6)	2 (13)	3 (14)
Early, non-ETP	3 (2)	0	1 (2)	0	2 (13)	0
Mature	15 (11)	3 (10)	6 (12)	1 (6)	0	5 (24)
NOS/NA	12 (9)	4 (13)	5 (10)	1 (6)	0	2 (10)
CR at start	20	4	9	1	3	3
ORR	109/113 (96)	25/26 (96)	39/40 (98)	16/16 (100)	13/13 (100)	16/18 (89)
CR/CRp	104/113 (92)	25/26 (96)	38/40 (95)	15/16 (94)	12/13 (92)	14/18 (78)
Median follow up (mos)	62	143	88	57	33	15
SCT in first remission	24 (18)	1 (3)	13 (26)	4 (23)	3 (19)	3 (14)

Abbreviations: ECOG, Eastern co-operative oncology group; PS, performance status; T-ALL, T-cell acute lymphoblastic leukemia; T-LL, T-cell lymphoblastic lymphoma; CNS, central nervous system; BM, bone marrow; ETP, early T-cell precursor; NOS, not otherwise specified; N/A, not available; CR, complete remission; ORR, overall response rate; SCT, allogeneic stem cell transplantation

Figure 1: Figure 1: Kaplan Meier estimates of overall survival (OS) of the study cohorts based on the drug combinations used




Figure 1

<https://doi.org/10.1182/blood-2023-179562>

Downloaded from http://ashpublications.net/blood/article-pdf/142/Supplement_1/963/2184263/blood-5567-main.pdf by guest on 18 May 2024